#United States #New York #Investor Claims #Faruqi LLP #Razolute

Investigation into Rezolute, Inc.

Faruqi & Faruqi, LLP, a prominent national securities law firm, has announced that it is conducting an investigation regarding potential claims from investors related to Rezolute, Inc. (NASDAQ: RZLT). This comes in light of alarming developments surrounding the company’s financial performance after it experienced a dramatic drop in share prices following unfavorable results from its clinical trials.

Background on the Situation

On December 11, 2025, shares for Rezolute plummeted significantly as news broke regarding the outcomes of its Phase 3 sunRIZE clinical trial aimed at testing the efficacy of its lead drug candidate, ersodetug, for treating congenital hyperinsulinism. The trial’s results failed to meet both its primary objectives and key secondary endpoints, which is worrying for stakeholders and investors alike. According to reports, the maximum dosage in the trial revealed reductions in hypoglycemia events that were not statistically significant when compared to placebo treatments.

As trading resumed, the stock price saw a staggering decline from the previous day’s close of approximately $10.94, plummeting to an intraday low of about $0.90, marking a shocking decrease of roughly 85-90%. This swift fall necessitated a halt in trading under the volatility controls implemented by NASDAQ.

The Role of Faruqi & Faruqi, LLP

In response to these events, Faruqi & Faruqi, with its extensive history of protecting investors, is reaching out to individuals who have incurred significant financial losses in Rezolute stocks or options. The firm urges impacted investors to contact its seasoned partner, James (Josh) Wilson, to explore their legal options. Faruqi & Faruqi is noted for having recovered hundreds of millions of dollars for investors since its inception in 1995, which reinforces their credibility in handling such sensitive matters.

How to Get In Touch

Those investors who experienced substantial losses and seek further information about their potential claims are encouraged to reach out directly. The contacts for inquiries include Faruqi & Faruqi at their main line, 877-247-4292 or the New York office at 212-983-9330 (Ext. 1310).

For ongoing updates and more information, individuals can visit Faruqi & Faruqi's website or check their social media channels on platforms like LinkedIn, X, and Facebook.

Faruqi & Faruqi maintains a commitment to handle all communications with confidentiality and encourages clients to discuss their cases in a secure environment.

Conclusion

The investigation into Rezolute serves as a timely reminder of the potential volatility and risks associated with investments in biotech companies, particularly in the context of clinical trials. As the situation develops, investors are urged to stay informed and consult with legal experts to safeguard their interests. Faruqi & Faruqi's investigation into potential claims signifies an important step for affected investors as they navigate the repercussions of investment losses.